Tuune to raise $4.6 million from investors led by venture capital firm Octopus Ventures.

Tuune, a London, UK-based femtech startup using AI and biological testing to match women with the most suitable contraception option, announced raising $4.6M in a fresh round of funding.

The money was raised from investors led by venture capital firm Octopus Ventures.

The proceeds will be used for launching its product in the US market as well as improve product, as it plans to build a more individualised medical system that puts hormones first, and claims it will transform the future of healthcare for all women and people with cycles.

Tuune, founded in 2018 by Peter Fish and Shardi Nahavandi, a personalised women’s healthcare company, re-inventing the way healthcare accesses the complexity of female hormones with a focus on individuality. The company works with clinicians who use its technology to provide insights and recommendations of birth control for women, based on comprehensive health history, lifestyle preferences, and hormone analysis. The company says that this individualised approach helps women alleviate their hormonal symptoms and conditions, including endometriosis, anxiety, weight gain, and acne.